Benzocaine Reference Standard — CAS 94-09-7, Ethyl 4-Aminobenzoate, Free Base

1. What this material is

This page describes benzocaine supplied as an analytical reference material: a weighed quantity of a single identified chemical substance, intended to serve as the point of comparison against which another sample is measured. Everything downstream of that vial — a retention time, a calibration curve, a peak assignment in a seized-material report, a release decision on an incoming batch — inherits its identity and its condition.

Benzocaine is the simplest member of the ester local anaesthetics: 4-aminobenzoic acid esterified with ethanol, and nothing else. The registry description states the relationship plainly, calling it a benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component, and describing it in a separate entry as an ester of 4-aminobenzoic acid lacking the terminal diethylamino group of procaine [1]. That structural minimalism is the source of every interesting property on this page. It is why the compound is a free base rather than a hydrochloride while its close relative is supplied as a salt (section 6). It is why the molecule is achiral and therefore free of the stereochemical failure modes that dominate more complex reference materials (section 3). And it is why its identity is unexpectedly hard to pin down: a small, symmetrical, nine-carbon molecule has a great many near neighbours, and several of them are its own manufacturing residues.

The substance is also unusually well documented. Where some entries in this catalogue rest on a handful of computed descriptors — chlodantane has no deposited spectrum of any kind — benzocaine carries proton, carbon-13 and nitrogen-15 nuclear magnetic resonance spectra, a two-dimensional correlation spectrum, three families of vibrational spectrum, six electron-ionisation and chemical-ionisation mass spectra, six tandem mass spectra, nineteen gas-chromatographic retention indices, eleven solved crystal structures and more than a century of pharmaceutical literature [1]. A page about this compound cannot honestly complain about missing data. It has to do something harder: explain why an abundance of reference data does not by itself confer certainty, and identify precisely which measurements are absent from an otherwise crowded record.

Three are. There is no polar-column retention index. There is no deposited ultraviolet curve, only an index number pointing into a commercial spectral collection. And the two vibrational spectra most sensitive to crystal form — the attenuated-total-reflectance infrared spectrum and the Raman spectrum — were both recorded on one sample from one supplier lot, in a compound with at least four documented solid forms [1]. Sections 8 and 10 return to each of these.

For the general terms on which this shop supplies reference materials, the surrounding reference standards category collects the rest of the catalogue on the same basis.

2. Identity and registry codes

Every identifier below is quoted from a public registry, with the registry named. Benzocaine has been in commerce since the beginning of the twentieth century, which means its documentary trail is long, multilingual and littered with trade names. Several of the identity traps in this section exist purely because of that history.

Machine-readable descriptors

Two of those rows deserve reading together. The SMILES string and the connectivity SMILES are character-for-character identical, which for most molecules would be a warning that stereochemistry had been lost somewhere in an import. Here it is simply true: the molecule has no stereochemistry to lose. Compare tadalafil, where the two strings differ and where storing the wrong one silently discards the only property that separates the substance from three others. For benzocaine that particular failure mode does not exist, and it is worth saying so plainly rather than leaving a reader to infer it from silence.

A complexity score of 151 across twelve heavy atoms places this among the least elaborate substances in the catalogue. That simplicity is not benign. The fewer distinguishing features a molecule has, the more compounds resemble it. Section 4 is the arithmetic of that sentence.

Identity traps

Five distinct ways to hold the wrong material, or to describe the right material wrongly, are documented in the public record for this compound.

The first row carries a numerical consequence worth stating explicitly, because it is the commonest arithmetic error made with any amine-bearing reagent. The ratio of hydrochloride mass to free-base mass here is 201.65 / 165.19 = 1.2207. A laboratory that weighs material believing it holds the hydrochloride, when in fact it holds the free base, over-delivers the benzocaine moiety by 22.1%. Running the error the other way, one gram of the hydrochloride would contain 819.2 mg of benzocaine base. Neither figure is exotic, and neither shows up in a chromatogram: an assay normalised against the same wrong standard reports 100%.

A symmetry in the pharmacopoeial impurity designations

3. Structure, and the absence of stereochemistry

Benzocaine is a para-disubstituted benzene carrying a primary aromatic amine at one position and an ethyl ester at the position opposite. The registry record states the stereochemical situation without ambiguity, and the four counters are quoted here verbatim because a great many catalogue descriptions of aminobenzoate esters get this wrong by implication rather than by assertion — by quoting an optical rotation, for instance, for a molecule that cannot possess one.

All four counters are zero. The molecule is achiral, has no cis/trans isomerism about any bond, and possesses no stereochemical property that could be measured, specified, or got wrong. It has no enantiomer, no diastereoisomer and no epimer. A specific rotation for this substance is zero by construction, and any non-zero figure attached to it in a supplier document is a description of something else in the bottle.

This places benzocaine at the opposite end of the catalogue from the compounds where configuration is the whole story. Tadalafil has two defined centres and four separately registered stereoisomers that mass spectrometry cannot tell apart. Alpha-GPC has one centre and a naming collision with its own antipode. Bromantane, like benzocaine, is achiral, and for a comparable reason: rigid symmetry and no sp³ carbon bearing four different groups. For benzocaine the practical consequence is a genuine simplification, and it should be taken as one. Chiral chromatography, cyclodextrin electrophoresis and chiroptical spectroscopy have nothing to contribute here, and a certificate offering them is offering a measurement of nothing.

What the symmetry does instead

The para substitution pattern creates a mirror plane through the ester and amine substituents, and that symmetry is directly visible in the deposited carbon-13 spectrum. Nine carbon atoms give seven resonances, not nine, because the two pairs of aromatic methine carbons are equivalent. The deposited peak list reads 166.93, 151.38, 131.55, 119.58, 113.74, 60.31 and 14.41 ppm [1]: carbonyl, the amine-bearing quaternary carbon, the equivalent pair ortho to the ester, the ester-bearing quaternary carbon, the equivalent pair ortho to the amine, the methylene and the methyl.

That line count is itself an analytical result. A 1,3-disubstituted isomer has no such mirror plane and gives nine carbon resonances; a 1,2-disubstituted isomer likewise gives nine. Counting lines in a carbon spectrum is therefore a decisive test of substitution pattern, requires no reference sample of the interfering isomer at all, and costs one experiment. It is the cheapest unambiguous discriminator available for this compound, and section 5 returns to it with the caveat it deserves.

The proton spectrum shows the same symmetry as a four-signal pattern: an AA′BB′ aromatic system with multiplets near 7.86 and 6.64 ppm, a quartet at 4.32 ppm and a triplet at 1.37 ppm, recorded at 600 MHz in deuterochloroform [1]. The clean two-doublet appearance of the aromatic region is characteristic of para substitution and is the first thing an experienced reader checks.

4. The central problem: a confirmatory pair that fails twice

Almost every laboratory that confirms benzocaine does it the same way: inject on a non-polar gas-chromatographic column, compare the retention index against a library value, and compare the electron-ionisation spectrum against a library spectrum. The two measurements are treated as orthogonal, and in general they are. For this compound they are not enough, and the reason is documented in the public record rather than being a matter of opinion.

Dimension one: mass

Read the third column. Unlike the stereoisomer problem, where records differ only in the second InChIKey block, here the first blocks differ — these are genuinely different connectivities, and a system that indexes on the InChIKey skeleton will keep them apart correctly. The failure is not in the database. It is in the instrument: the mass spectrometer sees a number that all five share.

Fragmentation narrows the field, but less than one would hope. The electron-ionisation spectrum of benzocaine is dominated by loss of the ethoxy radical to give the 4-aminobenzoyl cation at m/z 120, followed by loss of carbon monoxide to m/z 92 and ring fragmentation to m/z 65. Those three ions plus the molecular ion at 165 constitute the entire diagnostic content of the spectrum. Ethyl 3-aminobenzoate produces exactly the same four ions, because the substitution pattern does not survive the fragmentation [1][4].

Dimension two: retention index

The second half of the confirmatory pair is retention behaviour, expressed as a Kovats index so that it transfers between instruments. Nineteen values are deposited for benzocaine on standard non-polar stationary phases, all from the same data centre [1].

Three readings follow from that table, and they compound.

First, the impurity sits inside the parent's window. The single retention index deposited for 4-aminobenzoic acid, 1547, falls between the tenth and eleventh of benzocaine's nineteen values and lies two units from their median. On a non-polar column, and within the spread that the reference collection itself reports, the compound and its designated pharmacopoeial impurity are not resolved by index. The ortho isomer, by contrast, is separated by roughly 150 index units — the intramolecular hydrogen bond between an ortho amine and the ester carbonyl shortens its retention dramatically — and the isobaric carbamate is similarly far away. The compounds that separate well are not the ones a benzocaine sample is likely to contain.

Second, the process impurity overlaps the lower third. Ethyl 4-nitrobenzoate covers 1491 to 1527. Six of benzocaine's nineteen values — 1513, 1513, 1516, 1523, 1523 and 1526, that is 31.6% of the deposited set — lie at or below the nitro ester's maximum. Any tolerance window wide enough to accept a genuine benzocaine index from the low end of its own distribution is wide enough to accept the nitro ester.

Third, and most consequential, the orthogonal measurement does not exist for the analyte. A polar stationary phase separates aminobenzoates from nitrobenzoates decisively, because the polar column responds to the hydrogen-bond donor that the amine has and the nitro group lacks. The reference collection holds eight polar-column indices for ethyl 4-nitrobenzoate, two for the ortho isomer and one for the carbamate. It holds none for benzocaine. The instrument that would settle the question has reference values for every interfering compound and no reference value for the compound of interest, which means the comparison has to be made against a standard the laboratory measures itself — which is to say, against material like the one on this page.

The one place high-resolution mass spectrometry does help

In positive-mode tandem mass spectrometry the protonated molecule at m/z 166.086 fragments by loss of ethene to m/z 138.054, the protonated 4-aminobenzoic acid, and by loss of ethanol to m/z 120.044, the 4-aminobenzoyl cation. Both benzocaine and the meta isomer show this pair. The deposited spectra diverge at one ion, and the divergence is real rather than a matter of intensity [1][4].

The two ions near m/z 121 differ by 0.018 Da, which requires a resolving power of roughly 6,600 to separate — routine on a time-of-flight or orbital-trap instrument, impossible on a unit-resolution quadrupole. Their accurate masses point to different compositions. Benzocaine's 121.047 is consistent with the carbon-13 isotopologue of its own base peak at 120.0438; the meta isomer's 121.0288 is consistent with C₇H₅O₂⁺, that is, loss of ammonia from the m/z 138 ion. We report the observed masses as deposited and the composition assignment as an inference from accurate mass, not as the result of a labelling experiment. With that caveat, it is the only ion in either spectrum that distinguishes the two compounds, and it is invisible to the instrument class most laboratories use for routine confirmation.

5. Methods that do resolve the ambiguity

Five approaches address the problem set out above. Each has a published basis and each carries the same prerequisite: material of known identity to compare against. None is self-calibrating.

Counting carbon resonances

Section 3 established the arithmetic: para substitution gives seven carbon environments, meta and ortho give nine. This is the most decisive test available and it needs no reference sample of the interfering isomer, because the answer is a count rather than a comparison. Two caveats belong with it. The deposited benzocaine peak list is machine-readable and can be checked directly [1]. The deposited spectra for the meta isomer, by contrast, exist only as copyrighted images with no peak list at all [4] — so while the count argument follows soundly from molecular symmetry, a laboratory cannot verify the isomer half of it against a public numerical record. It has to run the experiment.

Orthogonal chromatography

A polar column resolves what a non-polar column does not, for the reason given in section 4. Because no polar-column index is deposited for benzocaine, the laboratory establishes its own value against a characterised standard once, and then owns a measurement the public record does not contain. The same logic applies in reversed-phase liquid chromatography, where a validated method separating benzocaine from preservatives and co-formulants in a semi-solid matrix has been published in full [32], and where the modern review of the field treats liquid chromatography and its ultra-high-performance variant as the stability-indicating reference techniques against which everything else is measured [31].

Ultraviolet detection with spectral confirmation

Benzocaine carries a strong aminobenzoate chromophore, and diode-array detection returns not just a peak area but a spectrum at every point across it. Peak purity assessment by spectral comparison across a peak catches co-elution that a single-wavelength trace hides. There is a documentary gap here that section 10 quantifies: the registry holds no deposited ultraviolet curve for benzocaine, only an index number into a commercial collection [1]. A laboratory therefore takes its absorption maximum and its absorptivity from a method paper or from its own standard, never from a reference record. Compare apigenin, a flavone whose two intense absorption bands make ultraviolet identification straightforward and whose spectral record is correspondingly better populated.

Vibrational spectroscopy, with a caution

Infrared and Raman spectra distinguish substitution patterns cleanly: the out-of-plane aromatic bending region separates 1,4-, 1,3- and 1,2-disubstituted rings by inspection. Three vibrational spectra are deposited for benzocaine, in transmission through a potassium bromide pellet, by attenuated total reflectance, and by Fourier-transform Raman [1]. The caution is that these same techniques are the ones most sensitive to crystal form, and this compound has at least four (section 8). A spectrum that differs from the deposited one may indicate a different substance or merely a different polymorph, and telling those two explanations apart requires powder diffraction or thermal analysis rather than more spectroscopy. Vibrational spectroscopy coupled with density functional calculations has been used precisely to confirm polymorph identity for this compound [26].

Chemically selective detection

The primary aromatic amine is a functional handle that none of the isobaric interferents shares in the same position, and several published methods exploit it directly. An indirect surface-enhanced resonance Raman assay determines benzocaine in pharmaceutical formulations by first converting the amine through azo coupling, turning a weakly scattering analyte into a strongly resonant dye [33]. Electrochemical approaches oxidise the amine at a defined potential, and the modern review catalogues boron-doped diamond and carbon nanocomposite electrodes as sensitive, low-detection-limit routes for this compound [31]. Voltammetry on additively manufactured graphene electrodes has been developed in the adjacent forensic context where benzocaine is one of the substances that must be told apart from the analyte of interest [36]. Selectivity in all of these comes from chemistry rather than from mass, which is exactly what section 4 says is needed.

6. Free base and hydrochloride: why this ester is not a salt

Benzocaine is supplied as the free base. Its nearest structural relative, procaine, is supplied as the hydrochloride. Both facts are correct, both are stable conventions of long standing, and the reason for the difference is a single number in each record.

The whole difference is in the third row. Procaine carries an aliphatic tertiary amine whose conjugate acid has a pK_a near nine, so at any ordinary pH it is protonated, and a hydrochloride of that amine is a stable, crystalline, freely water-soluble solid that stays a salt when dissolved. Benzocaine has no such centre. Its only basic site is the aromatic amine, delocalised into the ring and further deactivated by the para ester, and the pK_a of its conjugate acid is 2.51 [1]. A hydrochloride of a base that weak is a salt of a strong acid with a very weak base: dissolve it in water and it dissociates and hydrolyses back to the free base almost completely, leaving an acidic solution and a precipitate. The salt exists as a registry entity [7] and can be made under strongly acidic conditions; it is not a useful article of commerce, and that is why nobody ships it.

The same weak basicity explains a property that matters in the laboratory rather than on paper. Because the amine is only protonated below about pH 2.5, benzocaine is uncharged across the entire useful chromatographic range, which is why reversed-phase retention is essentially independent of mobile-phase pH above pH 4 and why ion-pairing reagents do nothing for it. The registry's qualitative solubility entries are consistent: soluble in acid and also soluble in dilute acids appear alongside the low neutral-water figure [1]. Dissolution in dilute hydrochloric acid is a solubilisation trick, not evidence that the material is a salt.

7. Two synthetic routes, two impurity profiles

Benzocaine is made two ways, and the public record names both. The registry's manufacturing entry states that benzocaine is produced by reduction of ethyl 4-nitrobenzoate with iron; a separate descriptive entry in the same record describes the compound as an ester made from 4-aminobenzoic acid and ethanol, that is, by direct esterification [1]. These are not variants of one process. They start from different materials, pass through different intermediates and leave different residues, and a purity specification written for one does not describe the other.

The last two rows carry the operational point. Both principal impurities are trivially separated by mass and neither is reliably separated by non-polar retention index. A gas-chromatographic method that identifies peaks by index and only then confirms by mass will therefore assign correctly; a method that screens by index and reports without confirming will not. That is an unusual ordering — for most compounds the index is the coarse filter and the mass the fine one — and it is worth stating because it inverts a habit.

The intermediate that is also a metabolite

Two further residues deserve a mention because they are invisible to the usual assay. Ethanol from the esterification route is a residual solvent that a chromatographic purity figure does not see, since it elutes with or before the solvent front in almost every method written for the product. And iron from the reduction route is an inorganic residue that no organic method sees at all. Neither is exotic and neither is alarming; both are simply outside what an area-percent purity number measures, which is the general point section 16 makes about purity figures.

8. Solid form: three polymorphs and a transition below room temperature

Benzocaine is a small, flexible, hydrogen-bonding molecule that crystallises easily and in more than one way. The crystallographic literature on it is deep, current and unusually well suited to a reference-materials discussion, because the phase behaviour has a transition temperature that sits inside the range of an ordinary laboratory.

Eleven unit cells are deposited for this compound in the crystallographic collections, all with four molecules in the cell [1]. They fall into three clearly separated groups: five monoclinic cells near a = 8.2, b = 5.4, c = 19.5–20.1 Å with β ≈ 91.5°; five monoclinic cells near a = 6.34, b = 5.17, c = 24.5–24.9 Å with β ≈ 96.3°; and one orthorhombic cell at 8.2424 × 5.3111 × 20.9044 Å. The two monoclinic families differ in their long axis by nearly five ångströms — these are genuinely different packings of the same molecule, not refinements of one.

Grinding changes the form

The finding with the most direct bearing on a laboratory routine is mechanical. A 2018 study prepared benzocaine polymorphs using techniques ordinarily employed to process powders rather than to make polymorphs, and reported that ball milling converted form III into form I, micro-milling yielded form II, and only cryogenic grinding preserved the starting form III [26]. The same work established that the forms differ in solubility, in apparent solubility and in permeability through an artificial membrane system, while all three were chemically stable under the accelerated conditions tested.

Homogenising a sample in a mortar before weighing is standard practice. For this compound it is a phase-change operation. The chemical identity is untouched — the assay does not move, the mass spectrum does not move, the carbon spectrum in solution does not move — but the powder diffraction pattern, the Raman spectrum, the dissolution profile and the differential scanning calorimetry trace all can. Anyone using benzocaine to calibrate a solid-state method should record what was done to the powder, because the record of the treatment is the only trace that the form may have changed.

The pattern is not unique to this molecule. The next homologue up the series, butyl 4-aminobenzoate, has its own set of polymorphs with solid- and solution-state thermodynamics characterised in the same laboratory tradition [30], which suggests the behaviour belongs to the aminobenzoate ester family rather than to benzocaine alone. The contrast with a genuinely single-form reference material is instructive: mebicar, for instance, presents no comparable body of polymorph work, and for such compounds the phrase white crystalline powder on a certificate carries the information it appears to carry. Here it does not.

9. Physicochemical data, with attribution per value

The registry record for benzocaine has a well-populated experimental-properties section built from several independent aggregators. Where those aggregators agree, that agreement is itself worth reporting. Where they disagree, this page reports the disagreement rather than choosing.

Where the record contradicts itself

The temperature attached to the solubility figure. Two aggregators report the identical number, 1310 mg·L⁻¹, and attach it to different temperatures: 30 °C in one record and 25 °C in the other. One of the two has copied a value and re-labelled its conditions. There is no way to tell from the record which, and averaging two temperatures would be meaningless. Anyone quoting an aqueous solubility for benzocaine should quote the number, the source and the stated temperature together, and should treat the five-degree ambiguity as real. It is not a small point for a compound whose polymorph transition sits at 29–30 °C (section 8): the two quoted temperatures straddle it.

The Sanford-Burnham figure is a bound, not a measurement. The entry reads greater than 24.8 µg·mL⁻¹. That is 24.8 mg·L⁻¹, and it is consistent with 1310 mg·L⁻¹ rather than contradicting it — a greater-than statement at the top of an assay range says only that the compound did not fall out of solution within the range tested. It is included here because such entries are routinely misquoted as measurements, and a solubility of 24.8 µg·mL⁻¹ for benzocaine would be wrong by a factor of fifty.

The collision cross-sections disagree by 14%. Three travelling-wave determinations for the protonated molecule give 148.2, 145.9 and 130.08 Å². The first two agree to within 1.6%; the third is 12% below the second. More awkwardly, the outlying [M+H]⁺ figure of 130.08 Å² is smaller than the sodium adduct value of 136.4 Å² reported alongside it, which is difficult to reconcile with an adduct that adds mass and volume. Ion mobility is increasingly used as an orthogonal identity dimension; for this compound the deposited reference values are not tight enough to carry that weight, and a laboratory intending to use cross-section as a confirmatory parameter should determine it in-house against a characterised standard.

What is genuinely well established. The melting point is quoted at 92 °C by three independent aggregators with no dissent, and the partition coefficient at 1.86 by three, with the computed value 1.9 landing within 0.04 of the experimental consensus. These are the two numbers on the page that can be used without a caveat, and a melting point that is both sharp and unanimously reported is the single most useful incoming-goods check available for this material: a depressed or broadened melt is a direct signal of moisture, of residual solvent or of a second component.

One further note on solubility for practical work. At roughly 1.3 g·L⁻¹ in neutral water, benzocaine is far more soluble than the poorly soluble reference standards in this catalogue — tadalafil measures three orders of magnitude lower — but it is still not a compound for aqueous stock solutions at working concentration. The published work on co-solvent solubilisation of hydrophobic compounds used benzocaine among its test set precisely because its solubility responds strongly and predictably to organic co-solvent fraction [35], which is the quantitative basis for the ethanol, methanol or acetonitrile stocks that methods for this compound generally specify.

10. Spectra: what exists, what does not

This is the section where benzocaine differs most sharply from the sparsely documented entries in this catalogue. The record is full. It is also, in three specific places, incomplete in ways that matter more than the overall abundance suggests.

Three observations follow, in ascending order of how much they matter.

First, there is no deposited ultraviolet curve. The record's ultraviolet entry is a catalogue number in a commercial spectral collection, not a spectrum. Benzocaine has a strong, well-behaved aminobenzoate chromophore, and a substantial share of published quantitative work on it uses liquid chromatography with ultraviolet or diode-array detection [31][32]. So this is a gap in deposition rather than in physics — but it means the absorption maximum and the molar absorptivity used to build a calibration have to come from a method paper or from the laboratory's own measurement, and never from a reference record. That is a small extra step, and it is also a small extra opportunity for two laboratories to be working from different numbers without either knowing it.

Second, the two most form-sensitive vibrational spectra come from a single lot. The attenuated-total-reflectance infrared spectrum and the Fourier-transform Raman spectrum were both recorded on material from one supplier, one catalogue number and one lot: Alltech 01425, lot 538. The KBr-pellet infrared spectrum is from a different sample, which is a real improvement over a record where all three vibrational spectra share one origin — but two of the three still describe one lot of one supplier's material. Given section 8, where the same molecule is documented in three ambient-pressure polymorphs, a high-pressure form and two distinct monoclinic packings, and given that vibrational spectroscopy is the technique family most sensitive to exactly that variable, the single-lot provenance is a genuine limitation. A material in a different polymorph will legitimately give a different Raman spectrum while being the same substance, and a comparison against these deposited spectra would flag it as a mismatch.

Third, and least visible: the record is asymmetric between the compound and its nearest interferent. Benzocaine's carbon-13 and proton spectra are deposited with machine-readable peak lists. The corresponding spectra for ethyl 3-aminobenzoate exist in the registry as copyrighted thumbnail images with no numerical peak list [4]. The comparison that section 5 identifies as the decisive one — seven carbon environments against nine — can therefore be reasoned soundly from molecular symmetry but cannot be checked against public numbers on the isomer side. A laboratory that wants that comparison in its records has to acquire it.

11. Stability, hydrolysis and the coloured degradation product

Two claims about benzocaine's stability circulate and appear to conflict. The registry states flatly that the compound is stable in air [1]. The 2026 critical review of analytical methods lists susceptibility to hydrolysis into 4-aminobenzoic acid among the reasons accurate quantification of this compound remains difficult [31]. Both are correct, and reconciling them is a useful exercise in reading a stability statement properly.

The reconciliation is in the pH dependence. The estimated half-lives are 91 years at pH 7 and 9 years at pH 8: an ester of a weakly basic aniline is simply not a fast-hydrolysing compound in neutral water, and a dry solid at ambient conditions is not hydrolysing at any rate a laboratory will notice. The review is describing something different — the behaviour of the compound in alkaline media, in formulated matrices with reactive excipients, and under the forcing conditions used for stability-indicating method development, all of which sit far from a sealed vial of dry powder. A stability statement without its conditions is not a statement. The two sources are not in conflict; they are answering different questions, and each is right about its own.

The degradation that announces itself

Two further degradation observations belong here. The registry notes that benzocaine is itself a photodegradation product of ethyl N-phenylcarbamate, formed under a high-pressure mercury lamp, and that it goes on to give the azo products of that carbamate [1]. This closes an unusual loop: an isobaric isomer of benzocaine converts photochemically into benzocaine, and benzocaine converts photochemically into coloured azo compounds. Light moves material along this series in a definite direction, and neither end of it is distinguishable from benzocaine by exact mass alone (section 4).

And the hydrolysis product is not an inert bystander. Section 2 established that 4-aminobenzoic acid is recorded as a designated pharmacopoeial impurity of benzocaine, and section 4 established that its deposited retention index sits inside benzocaine's own spread. The most likely chemical degradation of this material produces the one impurity that a non-polar gas-chromatographic index cannot resolve from it. That is the practical argument for storing the material dry, sealed and dark, and for using an orthogonal method rather than an index match when the question actually matters.

12. Hazard classification

The registry carries an aggregated GHS classification for benzocaine, and it is important to read what that aggregation is before relying on it.

Signal word: Danger. Precautionary codes recorded against the aggregation are P260, P261, P264, P270, P272, P273, P280, P302+P352, P308+P316, P321, P333+P317, P362+P364, P391, P405 and P501.

A second, independent classification that says something sharper

The same record carries classifications from Japan's National Institute of Technology and Evaluation, and these are worth quoting because they name the target organ where the European aggregation does not [1].

Two points. The organ named in parentheses is blood, in both the single-exposure and the repeated-exposure classes, which connects the hazard statement directly to the toxicology in section 13 rather than leaving H370 as an abstraction. And the environmental classification was revised downward between 2010 and 2018, from Category 2 to Category 3 — a reminder that classifications are living documents and that a safety data sheet's vintage is part of its content.

The registry's own hazards summary adds a cross-reactivity note that is directly relevant to anyone handling the material: it records that cross-reactivity exists between procaine, benzocaine and tetracaine, but not with lidocaine or the other amide-type local anaesthetics [1]. The structural basis is the shared 4-aminobenzoate ester motif, and the practical consequence is that a person sensitised to one ester-type compound in this family may react to the others. A Danish study of patch-test sensitivity prevalence tracked benzocaine and lidocaine reactivity over time and reported them as distinct phenomena with different trends [21]. This is a fact about the substance class, not a medical assessment of any individual, and it belongs on this page because it is a reason to handle the powder with gloves rather than a reason to consult anybody about anything.

13. Methaemoglobinaemia: a fact about the substance and its literature

The single best documented toxicological property of benzocaine is that it can oxidise haemoglobin iron from the ferrous to the ferric state, producing methaemoglobin, which does not carry oxygen. This is stated here as a fact about the substance and about the published record. Nothing in this section is guidance, and nothing in it describes any use of the material on this page, which is supplied for in-vitro laboratory work and for nothing else.

What the mechanism literature establishes

A 2016 study in Xenobiotica set out to identify which species actually does the oxidising [13]. Incubating benzocaine with a human hepatic subcellular fraction produced a chromatographic peak matching the hydroxylamine, ethyl 4-(hydroxyamino)benzoate. Exposing whole human blood to that hydroxylamine directly produced methaemoglobin in a concentration-dependent way without any metabolic activation, whereas benzocaine required roughly a twenty-five-fold higher concentration in the presence of an activating fraction to reach a comparable degree of formation. The same study examined two candidate lidocaine metabolites for comparison and reported that the hydroxylated xylidine produced the greater effect of the two.

Two consequences follow for a chemist rather than a clinician. The parent compound is not itself the oxidant; a metabolite is. And that metabolite is the same partial-reduction intermediate that section 7 identified in one of the two industrial synthetic routes [9]. The connection between an impurity-profile question and a toxicology question is unusually direct here, and it is the reason section 16 names partial-reduction intermediates explicitly among the things we do not certify.

What the case literature establishes

The clinical case record for this effect is large, old and consistent. Reports of benzocaine-associated methaemoglobinaemia appear across anaesthesia, emergency medicine, gastroenterology nursing, paediatrics and general therapeutics [15][16][17][18][19][20]. The registry's own excerpts record that infants and elderly patients were more likely to develop the condition, and name genetic reductase deficiencies, higher exposure, and denuded skin or mucous membranes among the risk factors identified in the literature [1]. A retrospective review across four regional poison centres covering children under eighteen from 1993 to 1996 is quoted in the same record, and the registry also reproduces case reports in which intravenous methylene blue reversed the cyanosis — that compound being the reducing agent that converts methaemoglobin back to haemoglobin, and one whose chemistry the catalogue covers on its own card [1].

What the regulatory record shows, quantified

The clearest way to show the weight regulators place on this property is to count labels. Querying the United States Food and Drug Administration's open label dataset gives figures that can be reproduced by anyone with a browser [12].

Two-thirds of benzocaine labels carry the warning, against fewer than one in five for the most widely used amide-type comparator — a ratio of about 3.5 to one on a dataset where the comparator has nearly three times as many label records overall. The comparator serves as the positive control: the query returns a substantial non-zero count for lidocaine, so the benzocaine figure reflects labelling practice rather than a search that only matches one word. A 2018 note in a nursing journal records the regulatory action in the United States that led to the current warning language on oral benzocaine products [14].

The literal warning text on those labels is worth quoting once, because it is the most concise statement of the phenomenon available and because it is a public regulatory document rather than an interpretation: “Use of this product may cause methemoglobinemia, a serious condition that must be treated promptly because it reduces the amount of oxygen carried in the blood. This can occur even if you have used this product before.” [12]. The same labels carry an allergy alert naming procaine, butacaine and benzocaine together, which is the labelling counterpart of the ester cross-reactivity noted in section 12.

14. Regulatory status by jurisdiction

Each statement in this section is a measurement against a named source, and each negative statement is accompanied by a positive control on the same source, so that a zero can be told apart from a broken search. Where no working instrument was available, this page says so rather than reporting a zero.

United States: an over-the-counter monograph ingredient

Benzocaine is an active ingredient recognised in United States over-the-counter drug monographs. Two are recorded in the registry's regulatory section: the anorectal drug product monograph, which lists benzocaine among the permitted local anaesthetic active ingredients at 5 to 20 per cent, and the external analgesic monograph, which lists it in a narrower band of 3 to 7.5 per cent in a water-soluble base for one specified category [1]. These are composition limits in a regulation, quoted as such; they describe those finished products and not the reagent on this page.

Two further United States classifications belong in the record. The Food and Drug Administration's pharmacological classification of benzocaine is Standardized Chemical Allergen [1] — that is, the substance is formally recognised as a diagnostic allergen and not only as an anaesthetic. And the Drug Enforcement Administration's National Forensic Laboratory Information System has tracked benzocaine since October 1998, in the class Other Substances [1]. That is a monitoring designation rather than a control schedule: benzocaine carries no United States controlled-substance schedule in its registry record. Being counted is not the same as being scheduled, and the reason it is counted is the subject of the last part of this section.

Poland: fifteen register records, one of them for the substance alone

Searching the Polish Register of Medicinal Products by active substance for Benzocainum returns fifteen records [11]. The field was validated before being trusted: the same query returns 51 records for Lidocainum, 225 for Ibuprofenum, 28 for Procainum, 87 for Tadalafilum and 42 for Sildenafilum, and returns zero for Chlodantanum, a substance that genuinely has no Polish authorisation. A field that discriminates across that range, in both directions, is a field whose values mean something.

Two features of that table are worth drawing out. Fourteen of the fifteen Polish records are combination products, which is unusual: for most substances the register is dominated by single-ingredient medicines. Benzocaine in Poland is almost always a component rather than a product, and that has a documentary consequence — an analyst working from a Polish authorisation dossier will rarely find a specification written for benzocaine on its own.

And one of the fifteen is not a treatment at all. The record classified under ATC V04CL, a patch preparation for provocation testing, is a diagnostic allergen panel [11]. Benzocaine appears there for the reason section 12 gives: it is a recognised contact sensitiser, formally designated as a standardised chemical allergen in the United States classification [1], and studied as such in dedicated prevalence work [21]. The same molecule appears in the same national register both as an ingredient of anaesthetic preparations and as a test reagent for detecting allergy to itself. That is not a contradiction; it is what a well-characterised sensitiser looks like in a regulatory database, and it is the clearest available argument for wearing gloves when weighing the powder.

Australia, and carcinogenicity

The registry records two Australian IMAP assessments for benzoic acid, 4-amino-, ethyl ester: an environment tier I assessment and a human health tier I assessment [1]. On carcinogenicity the registry summary states that there is no indication of carcinogenicity to humans and that the substance is not listed by IARC [1].

Anti-doping: not measured, and reported as not measured

Forensic chemistry: why a legal reagent is counted

Benzocaine is not a controlled substance in any jurisdiction examined here, and it is not a listed drug precursor. It is nonetheless one of the most frequently encountered substances in seized-material laboratories, because it is used as a cutting agent in illicit cocaine, and the quantitative literature on that is specific.

The reason this belongs on a reference-material page rather than in a footnote is that it is the largest single source of demand for benzocaine standards. A forensic laboratory reporting benzocaine present at 12% w/w in a seizure is making a quantitative statement that a court may act on, and that statement rests on a calibration curve, which rests on a standard. The concentration range in the literature — from a fraction of a per cent to well over half the mass of the sample — means the calibration has to be linear across more than two orders of magnitude. Section 4 explains why the identification half of the same report needs more than a library match, and section 7 explains why the material used as the calibrant should have a known synthetic origin.

Adulteration of consumer products is a recurring theme across this catalogue and takes a different form in each domain. The sildenafil card covers it from the pharmaceutical-falsification side, where the problem is an undeclared active substance added to a preparation; here the problem is a declared-nowhere diluent added to an illicit one. The analytical demand is the same in both cases: a characterised standard, and a method that does not rely on a single dimension of evidence.

15. Handling, storage and documentation

The guidance below follows from the classification in section 12, the solid-state behaviour in section 8 and the degradation chemistry in section 11. It concerns the handling of a laboratory reagent by trained personnel and nothing else.

One contrast worth naming, because it runs the other way. Benzocaine is not hygroscopic and does not require the moisture discipline that some reference standards in this catalogue demand — alpha-GPC is the catalogue's clearest example of a material that takes up water from room air and whose weighing has to be planned around that. Benzocaine is a well-behaved, sharply melting, air-stable crystalline solid. Its handling requirements come from sensitisation, from light, and from the solid state, not from the balance.

16. What we certify and what we do not

This section exists because the difference between a supplier's statement and a certified value is the difference a reference material is bought for. We would rather state the boundary plainly than let a page imply more than it can support.

17. Terms of supply

This material is supplied as a laboratory reagent and analytical reference material, for in-vitro laboratory use by qualified personnel in an appropriately equipped facility. It is not a medicinal product, not a dietary supplement, not a food, feed or cosmetic ingredient, and it is not supplied for administration to humans or animals in any form or by any route.

By ordering, the purchaser confirms that they are a professional user acquiring the material for laboratory purposes; that they will handle it in accordance with section 15 and their own institutional risk assessment; that they will not administer it to humans or animals, nor supply it to any person who intends to; and that they are responsible for compliance with all laws applicable at the destination, which for a substance that is an active pharmaceutical ingredient in the destination jurisdiction may include requirements that do not apply to ordinary reagents.

Nothing on this page is medical advice, nor an offer of a medicinal product, nor guidance on the use of any medicine. Statements about authorised medicines and over-the-counter monographs in section 14 describe those products and their regulatory frameworks; they describe neither this article nor any use of it. The toxicological material in section 13 is reported as a property of the substance and as a summary of published research, and for no other purpose.

18. Questions and answers

Is this the free base or the hydrochloride?

The free base, CAS 94-09-7. The registry record shows a formal charge of zero and one covalently bonded unit, which is what a free base looks like in a database [1]. A hydrochloride record does exist, CAS 23239-88-5 at 201.65 g·mol⁻¹ [7], but it is not the article of commerce and section 6 explains the chemical reason: with a conjugate-acid pK_a of 2.51, a benzocaine hydrochloride hydrolyses back to the base in water almost completely.

Why is procaine supplied as a hydrochloride when benzocaine is not?

Because procaine has a second basic centre that benzocaine lacks. Its aliphatic tertiary amine has a basic pK_a near nine, so it stays protonated at ordinary pH and forms a stable, freely water-soluble hydrochloride [8]. Benzocaine's only basic site is the aromatic amine, delocalised into the ring and deactivated by the ester opposite it. Removing the diethylaminoethyl group is precisely what converts procaine into benzocaine, and it is also what removes the salt-forming handle.

Can I confirm identity by GC-MS library match?

You can confirm the compound class, which is a real result. You cannot safely confirm the isomer. Ethyl 3-aminobenzoate has the same molecular formula, the same monoisotopic mass to nine decimal places and the same four principal electron-ionisation ions at m/z 120, 165, 92 and 65 [1][4]. Worse, benzocaine's own five deposited electron-ionisation spectra disagree among themselves on the 165:120 intensity ratio by more than the isomer differs from any of them — in one of those five spectra the base peak is 165 rather than 120. Section 4 sets out the numbers.

What about retention index as a second dimension?

On a standard non-polar column it does not close the gap. Nineteen deposited values for benzocaine span 1513 to 1578, and the single deposited value for its designated pharmacopoeial impurity, 4-aminobenzoic acid, is 1547 — two units from the median of that set [1][2]. Ethyl 4-nitrobenzoate covers 1491 to 1527, overlapping the lower third [3]. The measurement that would resolve all of this is a polar-column index, and the reference collection has one for each of the interferents and none for benzocaine.

Then what actually distinguishes benzocaine from its meta isomer?

Three things, in descending order of decisiveness. Counting carbon-13 resonances: the para compound has a mirror plane and gives seven signals for nine carbons, while the meta compound has none and gives nine. A polar-column separation, once you have established the index against a characterised standard. And, on a high-resolution instrument, the ion near m/z 121: the meta isomer's deposited spectra show 121.0288 where benzocaine shows 121.047, a difference of 0.018 Da needing about 6,600 resolving power [1][4].

Does the compound have stereoisomers?

No. All four stereodescriptor counters in the registry record read zero, the InChI string carries no stereo layer, and the molecule is achiral [1]. It has no enantiomer and no diastereoisomer, its specific rotation is zero by construction, and chiral chromatography has nothing to separate. This is one of the few analytical questions about benzocaine with a clean, short answer.

Which polymorph is supplied?

We do not certify one, and section 16 says so explicitly. The literature documents three ambient-pressure forms plus a high-pressure form, with forms I and II enantiotropically related and a transition temperature of 29–30 °C [25][26][27][28][29]. Since that transition sits inside the range an ordinary laboratory and an ordinary shipment experience, the form present in a given container is a function of its thermal history. If solid form matters to your work, determine it by powder diffraction and thermal analysis on the material you hold.

Is it safe to grind the powder before weighing?

Chemically, yes; for solid-state work, no, or at least not without recording it. A 2018 study reported that ball milling converted form III to form I, micro-milling gave form II, and only cryogenic grinding preserved the starting form [26]. The assay, the solution-state spectra and the mass spectrum are unaffected. The diffraction pattern, the Raman spectrum and the dissolution behaviour can all change.

How soluble is it in water?

About 1310 mg·L⁻¹ — and the record does not agree with itself on the temperature, one aggregator attaching that number to 25 °C and another to 30 °C [1]. A third entry, greater than 24.8 µg·mL⁻¹ at pH 7.4, is a lower bound from an assay range rather than a measurement, and quoting it as a solubility understates the true figure by about fiftyfold. Practically: dilute aqueous standards are feasible, aqueous stock solutions are not, and ethanol, methanol or acetonitrile is the usual choice.

Does it need refrigeration?

We make no case for it. The registry records the compound as stable in air, the melting point is a comfortable 92 °C, and refrigerating a container that is then opened in a warm room invites condensation [1]. What the material does need is protection from light, a dry closed container, and a store that stays below the 29–30 °C polymorph transition rather than cycling across it [27].

My sample has gone yellow. Does that matter?

Yes, and it is useful information rather than merely cosmetic. The registry records that benzocaine is susceptible to direct photolysis and degrades to azo and coloured products [1]; aromatic primary amines couple oxidatively to intensely coloured azo compounds. Most reference standards degrade invisibly, so a compound whose earliest degradation signal is visible to the eye is doing you a favour. Investigate rather than dismiss it, and check the storage conditions that allowed it.

What is the relationship between benzocaine and 4-aminobenzoic acid?

Three relationships at once, which is what makes the pair interesting. The acid is the starting material for one of the two documented synthetic routes. It is the hydrolysis product of the ester. And each compound is recorded in the registry as a designated pharmacopoeial impurity of the other — the acid as Benzocaine EP Impurity G [2], the ester as Aminobenzoic acid impurity B [1]. We quote those designations from the registry's synonym fields; we have not read the monograph texts and reproduce no limits from them.

Why does the page spend so long on methaemoglobinaemia if this is a reagent?

Because it is the best-documented property of the substance and because two-thirds of United States drug label records containing benzocaine carry a warning about it, against fewer than one in five for the amide-type comparator [12]. Section 13 reports it as a fact about the substance and about the published literature, including the finding that the active oxidant is a hydroxylamine metabolite rather than the parent compound [13] — and that same hydroxylamine is a partial-reduction intermediate of one of the two industrial synthetic routes [9]. That connection is a chemistry question about impurity profiles, which is why it appears twice on this page.

Is benzocaine a controlled substance?

Not in any jurisdiction examined here. It carries no United States controlled-substance schedule in its registry record, and it is not a listed drug precursor. It has, however, been tracked by the United States forensic laboratory reporting system in the class Other Substances since October 1998 [1], because it is used as a cutting agent in illicit cocaine — found in 5.17% of one set of 116 seized samples, at levels from 0.4% to 58.3% [37]. Being counted and being scheduled are different states.

Do you supply a certificate of analysis?

Lot documentation accompanies the material. What that documentation does and does not cover is set out in section 16, including the items we do not certify: solid form, residual 4-aminobenzoic acid, residual nitro-route intermediates, residual solvents and inorganic residues, water content, ultraviolet absorptivity and polar-column retention index. We would rather name those gaps than let a certificate imply coverage it does not have.

References

Registry and database records

1. National Center for Biotechnology Information. 2026. "PubChem Compound Summary for CID 2337, Benzocaine." PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/2337.
2. National Center for Biotechnology Information. 2026. "PubChem Compound Summary for CID 978, 4-Aminobenzoic Acid." PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/978.
3. National Center for Biotechnology Information. 2026. "PubChem Compound Summary for CID 7457, Ethyl 4-Nitrobenzoate." PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/7457.
4. National Center for Biotechnology Information. 2026. "PubChem Compound Summary for CID 11400, Ethyl 3-Aminobenzoate." PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/11400.
5. National Center for Biotechnology Information. 2026. "PubChem Compound Summary for CID 6877, Ethyl 2-Aminobenzoate." PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/6877.
6. National Center for Biotechnology Information. 2026. "PubChem Compound Summary for CID 7591, Ethyl N-Phenylcarbamate." PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/7591.
7. National Center for Biotechnology Information. 2026. "PubChem Compound Summary for CID 10214462, Benzocaine Hydrochloride." PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/10214462.
8. National Center for Biotechnology Information. 2026. "PubChem Compound Summary for CID 4914, Procaine." PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/4914.
9. National Center for Biotechnology Information. 2026. "PubChem Compound Summary for CID 11622443, Ethyl 4-(Hydroxyamino)benzoate." PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/11622443.

Regulatory and register sources

10. European Chemicals Agency. 2026. "Benzocaine — substance information, EC 202-303-5, registry entry 100.002.094." ECHA. https://chem.echa.europa.eu/100.002.094.
11. Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych. 2026. "Rejestr Produktów Leczniczych — substancja czynna Benzocainum." https://rejestry.ezdrowie.gov.pl/rpl/search/public.
12. United States Food and Drug Administration. 2026. "openFDA Drug Label API, dataset last updated 22 August 2026." openFDA. https://open.fda.gov/apis/drug/label/.

Methaemoglobinaemia, sensitisation and the ester anaesthetics

13. Hartman, Neil, Hongfei Zhou, Jinzhe Mao, Daniel Mans, Michael Boyne, and Vikram Patel. 2016. "Characterization of the Methemoglobin Forming Metabolites of Benzocaine and Lidocaine." Xenobiotica 47 (5): 431–438. https://doi.org/10.1080/00498254.2016.1196402.
14. Aschenbrenner, Diane S. 2018. "Warning for Oral Drugs Containing Benzocaine." American Journal of Nursing 118 (9): 23–24. https://doi.org/10.1097/01.NAJ.0000544976.10560.e6.
15. Lehr, Jodi, Aaron Masters, and Blythe Pollack. 2012. "Benzocaine-Induced Methemoglobinemia in the Pediatric Population." Journal of Pediatric Nursing 27 (5): 583–588. https://doi.org/10.1016/j.pedn.2012.07.003.
16. Hegedus, Frederick, and Kathleen Herb. 2005. "Benzocaine-Induced Methemoglobinemia." Anesthesia Progress 52 (4): 136–139. https://doi.org/10.2344/0003-3006(2005)52[136:BM]2.0.CO;2.
17. Bong, Choon L., Jessica Hilliard, and Christian Seefelder. 2008. "Severe Methemoglobinemia from Topical Benzocaine 7.5% Use for Teething Pain in a Toddler." Clinical Pediatrics 48 (2): 209–211. https://doi.org/10.1177/0009922808324491.
18. Moos, Daniel D., and James D. Cuddeford. 2007. "Methemoglobinemia and Benzocaine." Gastroenterology Nursing 30 (5): 342–345. https://doi.org/10.1097/01.SGA.0000296253.78457.f4.
19. Kaufman, Michael R., and Rony K. Aouad. 2017. "Benzocaine-Induced Methemoglobinemia." The Journal of Emergency Medicine 53 (6): 912–913. https://doi.org/10.1016/j.jemermed.2017.09.004.
20. Khanal, Subrat, Ritu Modi, Komal Akhtar, and Anil Ghimire. 2018. "Benzocaine-Associated Methemoglobinemia." American Journal of Therapeutics 25 (6): e771–e772. https://doi.org/10.1097/MJT.0000000000000782.
21. Thyssen, Jacob P., Kåre Engkilde, Torkil Menné, and Jeanne D. Johansen. 2011. "Prevalence of Benzocaine and Lidocaine Patch Test Sensitivity in Denmark: Temporal Trends and Relevance." Contact Dermatitis 65 (2): 76–80. https://doi.org/10.1111/j.1600-0536.2010.01858.x.

Solid-state form and crystallography

22. Lynch, Daniel E., and Ian McClenaghan. 2002. "Monoclinic Form of Ethyl 4-Aminobenzoate (Benzocaine)." Acta Crystallographica Section E 58 (7): o708–o709. https://doi.org/10.1107/S1600536802009674.
23. Chan, Eric J., A. David Rae, and T. Richard Welberry. 2009. "On the Polymorphism of Benzocaine; a Low-Temperature Structural Phase Transition for Form (II)." Acta Crystallographica Section B 65 (4): 509–515. https://doi.org/10.1107/S0108768109018898.
24. Chan, Eric J., and T. Richard Welberry. 2010. "Precursor Effects of the Orthorhombic to Monoclinic Phase Transition in Benzocaine Form (II) Revealed by X-ray Diffuse Scattering." Acta Crystallographica Section B 66 (2): 260–270. https://doi.org/10.1107/S0108768110001527.
25. Gana, Inès, Maria Barrio, Bernard Do, Josep-Lluís Tamarit, René Céolin, and Ivo B. Rietveld. 2013. "Benzocaine Polymorphism: Pressure–Temperature Phase Diagram Involving Forms II and III." International Journal of Pharmaceutics 456 (2): 480–488. https://doi.org/10.1016/j.ijpharm.2013.08.031.
26. Paczkowska, Magdalena, Gabriela Wiergowska, Andrzej Miklaszewski, Anna Krause, Magdalena Mroczkowka, and Przemysław Zalewski. 2018. "The Analysis of the Physicochemical Properties of Benzocaine Polymorphs." Molecules 23 (7): 1737. https://doi.org/10.3390/molecules23071737.
27. Cheuk, Dominic, Michael Svärd, and Åke C. Rasmuson. 2020. "Thermodynamics of the Enantiotropic Pharmaceutical Compound Benzocaine and Solubility in Pure Organic Solvents." Journal of Pharmaceutical Sciences 109 (11): 3370–3377. https://doi.org/10.1016/j.xphs.2020.07.022.
28. Patyk-Kaźmierczak, Ewa, and Michał Kaźmierczak. 2020. "A New High-Pressure Benzocaine Polymorph — Towards Understanding the Molecular Aggregation in Crystals of an Important Active Pharmaceutical Ingredient." Acta Crystallographica Section B 76 (1): 56–64. https://doi.org/10.1107/S2052520619016548.
29. Rietveld, Ivo B., Hiroshi Akiba, Osamu Yamamuro, Maria Barrio, René Céolin, and Josep-Lluís Tamarit. 2023. "The Phase Diagram of the API Benzocaine and Its Highly Persistent, Metastable Crystalline Polymorphs." Pharmaceutics 15 (5): 1549. https://doi.org/10.3390/pharmaceutics15051549.
30. Svärd, Michael, Lai Zeng, Masood Valavi, Gamid Rama Krishna, and Åke C. Rasmuson. 2019. "Solid and Solution State Thermodynamics of Polymorphs of Butamben (Butyl 4-Aminobenzoate) in Pure Organic Solvents." Journal of Pharmaceutical Sciences 108 (7): 2377–2382. https://doi.org/10.1016/j.xphs.2019.02.013.

Analytical methods, solubility and stability

31. Barzani, Hemn A. H., Rebaz Anwar Omer, Khalamala Ibrahim Salih Barzani, Zanco Hassan Jawhar, Seerwan Hamadameen Sulaiman, and Hoshyar Saadi Ali. 2026. "Evolving Analytical Techniques for the Determination of Benzocaine and Its Metabolites: A Critical Review." Critical Reviews in Analytical Chemistry, 1–22. https://doi.org/10.1080/10408347.2026.2634888.
32. Pérez-Lozano, P., E. García-Montoya, A. Orriols, M. Miñarro, J. R. Ticó, and J. M. Suñé-Negre. 2005. "A New Validated Method for the Simultaneous Determination of Benzocaine, Propylparaben and Benzyl Alcohol in a Bioadhesive Gel by HPLC." Journal of Pharmaceutical and Biomedical Analysis 39 (5): 920–927. https://doi.org/10.1016/j.jpba.2005.05.033.
33. Zhao, Chao-Yang, Huimin Sui, Endi Xue, Li Li, Jie Zhang, and Tao Xu. 2022. "Determination of Benzocaine in Pharmaceutical Formulations by Indirect SERRS Assay Combined with Azo Coupling." Molecules 27 (14): 4492. https://doi.org/10.3390/molecules27144492.
34. Köllmer, Melanie, Carmen Popescu, Prashanth Manda, Leon Zhou, and Richard A. Gemeinhart. 2013. "Stability of Benzocaine Formulated in Commercial Oral Disintegrating Tablet Platforms." AAPS PharmSciTech 14 (4): 1333–1340. https://doi.org/10.1208/s12249-013-0015-5.
35. Miyako, Yasuhiro, Nawel Khalef, Katsumi Matsuzaki, and Rodolfo Pinal. 2010. "Solubility Enhancement of Hydrophobic Compounds by Cosolvents: Role of Solute Hydrophobicity on the Solubilization Effect." International Journal of Pharmaceutics 393 (1–2): 48–54. https://doi.org/10.1016/j.ijpharm.2010.03.059.
36. Rocha, Raquel G., Julia S. Ribeiro, Mário H. P. Santana, Eduardo M. Richter, and Rodrigo A. A. Muñoz. 2021. "3D-Printing for Forensic Chemistry: Voltammetric Determination of Cocaine on Additively Manufactured Graphene–Polylactic Acid Electrodes." Analytical Methods 13 (15): 1788–1794. https://doi.org/10.1039/d1ay00181g.

Forensic chemistry and adulteration

37. Fiorentin, Taís Regina, Melissa Fogarty, Renata Pereira Limberger, and Barry Kerr Logan. 2019. "Determination of Cutting Agents in Seized Cocaine Samples Using GC–MS, GC–TMS and LC–MS/MS." Forensic Science International 295: 199–206. https://doi.org/10.1016/j.forsciint.2018.12.016.
38. Laposchan, Sophia, Ruben F. Kranenburg, and Arian C. van Asten. 2022. "Impurities, Adulterants and Cutting Agents in Cocaine as Potential Candidates for Retrospective Mining of GC–MS Data." Science & Justice 62 (1): 60–75. https://doi.org/10.1016/j.scijus.2021.11.004.
39. Saraghi, Mana, and Elliot V. Hersh. 2014. "Potential Diversion of Local Anesthetics from Dental Offices for Use as Cocaine Adulterants." The Journal of the American Dental Association 145 (3): 256–259. https://doi.org/10.14219/jada.2013.33.
40. Fiorentin, Taís R., Barry K. Logan, David M. Martin, Thom Browne, and Eric F. Rieders. 2020. "Assessment of a Portable Quadrupole-Based Gas Chromatography Mass Spectrometry for Seized Drug Analysis." Forensic Science International 313: 110342. https://doi.org/10.1016/j.forsciint.2020.110342.
41. Kudlacek, Oliver, Niklas Senning, Alexandra Karden, Iina Ludwig, Julia Bicher, and Fatemeh Kooti. 2025. "Health Risks of Cocaine Adulteration: Local Anesthetics as Modulators of Monoamine and Organic Cation Transporters." Frontiers in Pharmacology 16: 1699035. https://doi.org/10.3389/fphar.2025.1699035.